Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas (Q38708463)

5 September 2017

title

Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas (English)

1 reference

5 September 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Aude Ingels

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Carina Dinhof

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Lucia Maddau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Antonio Evidente

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Bieke Dejaegher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Véronique Mathieu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

1 reference

7 April 2017

1 reference

Cancer Chemotherapy and Pharmacology

5 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

971-983

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28389780%20AND%20SRC:MED&resulttype=core&format=json

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Key regulators of apoptosis execution as biomarker candidates in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Temozolomide for the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Studies on structure-activity relationship of sphaeropsidins A-F, phytotoxins produced by Sphaeropsis sapinea f. sp. cupressi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Smardaesidins A-G, isopimarane and 20-nor-isopimarane diterpenoids from Smardaea sp., a fungal endophyte of the moss Ceratodon purpureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Transporters beyond transport. Focus on "Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Ion channels involved in cell volume regulation: effects on migration, proliferation, and programmed cell death in non adherent EAT cells and adherent ELA cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Experimental designs and their recent advances in set-up, data interpretation, and analytical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Simultaneous determination of copper, bismuth and lead by adsorptive stripping voltammetry in the presence of thymolphthalexone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Resistance to BRAF-targeted therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Experimental design and multiple response optimization. Using the desirability function in analytical methods development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Application of response surface methodology and artificial neural network methods in modelling and optimization of biosorption process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Magnesium depletion enhances cisplatin-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Cell death after co-administration of cisplatin and ethacrynic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

Evaluation of in vitro anticancer activity of sphaeropsidins A–C, fungal rearranged pimarane diterpenes, and semisynthetic derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-017-3293-X